Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Adjuvant properties of bacterial cell wall components like MPLA (monophosphoryl lipid A) are well described and have gained FDA approval for use in vaccines such as Cervarix. MPLA is the product of chemically modified lipooligosaccharide (LOS), altered to diminish toxic proinflammatory effects while...

Full description

Bibliographic Details
Main Authors: Kelsey A. Gregg, Erin Harberts, Francesca M. Gardner, Mark R. Pelletier, Corinne Cayatte, Li Yu, Michael P. McCarthy, Jason D. Marshall, Robert K. Ernst, Nancy E. Freitag
Format: Article
Language:English
Published: American Society for Microbiology 2017-05-01
Series:mBio
Online Access:http://mbio.asm.org/cgi/content/full/8/3/e00492-17

Internet

http://mbio.asm.org/cgi/content/full/8/3/e00492-17

Similar Items